NEW YORK, Sept. 23 (GenomeWeb News) - Shares of Gene Logic's are down 14.8 percent, or $.83, at $4.82 in afternoon trading following news yesterday that the value of the goodwill asset from its 2003 acquisition of TherImmune Research is impaired.
The company will announce the amount of the impairment by Nov. 9 after completing its review with a third-party valuation specialist.